U.S. Markets open in 7 mins

Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology

Stock Monitor: Alliqua BioMedical Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 07, 2017 / Active-Investors issued a free report on Shire PLC (NASDAQ: SHPG), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=SHPG as the Company's latest news hit the wire. On December 05, 2017, the Company declared that it has entered into a collaboration with Rani Therapeutics to exclusively conduct research on the use of the Rani Pill(TM) technology for the oral delivery of factor VIII (FVIII) therapy, for delivering treatment to patients with hemophilia A. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Alliqua BioMedical, Inc. (NASDAQ: ALQA), which also belongs to the Healthcare sector as the Company Shire. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALQA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Shire most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:

www.active-investors.com/registration-sg/?symbol=SHPG

As part of the agreement, Shire has made an equity investment into Rani Therapeutics and will get an exclusive option to negotiate a worldwide license to develop and commercialize the FVIII therapy following completion of feasibility studies. Other details of the agreement remain undisclosed.

Collaboration to Reduce Patients Chronic Burden of Hemophilia by Researching an Oral Option to Deliver FVIII

Fritz Scheiflinger, Head of Global Research of Shire, stated that with the Company`s in-depth scientific expertise and leadership position in hemophilia and Rani's deep experience in engineering and material science, Shire is excited by the potential of this partnership to reduce the chronic burden of hemophilia on patients` everyday lives by researching an oral option to deliver FVIII to patients. Fritz added that the Company strives to provide hemophilia patients with innovative therapies that are effective and do not expose patients to additional risks.

Shire Collaborated with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors

On August 25, 2017, Shire entered into a collaboration with MicroHealth to support a free and secure care monitoring tool for hemophilia A and B patients with inhibitors and their care teams. MicroHealth developed the tool, in the form of an app, to help improve hemophilia patient care and outcomes through the ability to set reminders, track, store and selectively share personal health data, including photos and bleed alerts, with care team members. Shire's collaboration with MicroHealth helped the start-up customize the tool with new features and information specifically for the 5%-7% of hemophilia patients with inhibitors.

What is Hemophilia?

Hemophilia is one of a group of inherited bleeding disorders that cause abnormal or exaggerated bleeding and poor blood clotting. It refers to two specific conditions, hemophilia A and hemophilia B. Hemophilia A is caused by a deficiency of clotting Factor VIII, and while hemophilia B results from a deficiency of Factor IX. Symptoms of the disease includes excessive bleeding from any site in the body, long-term damage to joints from repeated bleeding episodes is characteristic. Currently, no oral therapies exist for the treatment of hemophilia.

About Rani Pill

Rani Pill is a capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall. Since the intestines do not have sharp pain receptors, the intestinal delivery is expected to be pain free.

About Shire PLC

Founded in 1986 and headquartered in Dublin, Ireland, Shire is the global leader in serving patients with rare diseases and other highly specialized conditions. The Company focuses on developing new medicines in its chosen therapeutic areas through its extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe.

About Rani Therapeutics

Established in 2012, and spun out of InCube Labs, Rani Therapeutics develops oral biotherapeutics technologies for the oral delivery of large drug molecules that include peptides, proteins, and antibodies. The Company has developed a technology platform to convert injectable drugs, such as TNF-alpha Inhibitors, interleukin antibodies, and basal insulin, among others, into pills. Rani Therapeutics is based in San Jose, California.

Stock Performance Snapshot

December 06, 2017 - At Wednesday's closing bell, Shire's stock declined 1.28%, ending the trading session at $142.69.

Volume traded for the day: 1.07 million shares.

After yesterday's close, Shire's market cap was at $43.20 billion.

Price to Earnings (P/E) ratio was at 26.86.

The stock has a dividend yield of 0.64%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors